As per the agreement, Ipsen is granted two exclusive options to exclusively license Oncodesign’s LRRK2 inhibitor program with worldwide development, manufacturing and commercialization rights.
Oncodesign will receive milestone payments potentially totaling EUR115m for the development of molecules in two or more indications, and tiered royalties on net sales.
Oncodesign is entitled to a technology access fee, funding of the program’s research and early development activities.
Partnership is based on Oncodesign’s Nanocyclix Technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Oncodesign CEO and founder said the agreement allows them to advance the series of attractive LRRK2 inhibitors together with a partner with recognized expertise in CNS Research.